Together, they are furthering NuView Life Science’s mission: to change the way many types of cancer are diagnosed and treated using precision medicine technology. Diagnosing and treating cancer with a targeted, specific approach to the disease will help to increase positive patient outcomes while also driving down costs incurred by patients, healthcare providers, and third-party insurance payers.
Meet Our Management Team
He has served as Chief Medical Officer for multiple companies in this space including Genzyme Genetics, Lineagen, Rosetta Genomics, Generation Health, Helicos Biosciences, Good Start Genetics, Celula, Ambry Genetics, Alfigen. He has co-founded several successful ventures, and served as a consultant to a wide variety of entities ranging from large and small clinical laboratories, IVD and Biotech companies, investor groups, regulatory agencies, payers and legal firms.
In addition to clinical and technical expertise he has laboratory and general operational, business development, medical affairs/marketing and sales experience. He had formal training and both public and private sector experience in reimbursement and managed care. He has had international experience in Europe, Japan and China.
He is a graduate of Yale University and Albany Medical College and Board Certified in Pediatrics and Medical Genetics.
Currently he co-directs a novel reproductive genetics lab, Predictive Laboratories in Salt Lake City, and serves as a senior executive advisor to a number of start-ups and other clients. He serves on the Board of Directors and SAB of the TESS Foundation, a non-profit focused on treatments for epilepsy and symptoms of SLC13A5.
Most recently, Steven served as Vice President, Health Systems & National Accounts with Becton Dickinson Inc., and Corporate Vice President National Accounts for CR Bard Inc., implementing market channel strategy and overseeing corporate relationships at the largest health networks in the United States. Prior to this, Steven held strategic development roles in both start-up ventures and in large global healthcare corporations. He has marketed technologies in the areas of: Tumor Ablation, Oncology Drug Delivery, Cardiovascular Intervention, Imaging, Urology, General Surgery, and Diagnostics.
He is a graduate of Pepperdine University, California, in Business Administration with an undergraduate focus in Statistics.